You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC)

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

HER2+ Advanced Breast Cancer, Other Solid Tumors Trial (ADCC-R-Epo-R T-cells + Trastuzumab, Erythropoietin beta, Fludarabine and

Not yet recruiting
  • HER2+ Advanced Breast Cancer
  • Other Solid Tumors
  • ADCC-R-Epo-R T-cells + Trastuzumab
  • +2 more
  • (no location specified)
Aug 31, 2023

Rheumatoid Arthritis, Autoimmune Rheumatologic Disease, Systemic Lupus Erythematosus Trial in Québec (COVID-19 vaccine)

Recruiting
  • Rheumatoid Arthritis
  • +8 more
  • COVID-19 vaccine
  • Montréal, Quebec, Canada
  • +1 more
Jan 13, 2023

Breast Cancer Trial in Guangzhou (Inetetamab Plus Cyclophosphamide Metronomic Chemotherapy Plus AI)

Recruiting
  • Breast Cancer
  • Inetetamab Plus Cyclophosphamide Metronomic Chemotherapy Plus AI
  • Guangzhou, Guangdong, China
    Shusen Wang
Jul 1, 2021

Colorectal Cancer, ADCC Trial in Napoli (Folfiri/Cetuximab)

Recruiting
  • Colorectal Cancer
  • ADCC
  • Napoli, Italy
    Istituto Nazionale dei Tumori,
Sep 1, 2021

Breast Cancer, Uterine Cancer, Ovarian Cancer Trial in Denmark, France, Spain (GEN1047 is a bispecific antibody that induces

Recruiting
  • Breast Cancer
  • +3 more
  • GEN1047 is a bispecific antibody that induces T-cell mediated cytotoxicity of B7H4-positive cells.
  • Copenhagen, Denmark
  • +5 more
Jul 25, 2022

Lymphoma, Primary Effusion Trial run by the National Cancer Institute (NCI) (Daratumumab SC)

Not yet recruiting
  • Lymphoma, Primary Effusion
  • Daratumumab SC
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Jun 23, 2023

Subclass of Donor-specific Antibody asRisk Factor of Antibody

Active, not recruiting
  • Antibody-mediated Rejection
    • Montpellier, Hérault, France
      CHU Lapeyronie
    Jan 18, 2023

    Pancreatic Cancer Trial (BNT321 Dose Level 1, BNT321 Dose Level 2, mFOLFIRINOX)

    Not yet recruiting
    • Pancreatic Cancer
    • BNT321 Dose Level 1
    • +3 more
    • (no location specified)
    Sep 29, 2023

    Circulating Cluster of Differentiation 4 Positive 28 Null T

    Not yet recruiting
    • Autoimmune Hemolytic Anemia
      • (no location specified)
      Jan 31, 2023

      Ependymoma, Recurrent Childhood, Ependymoma Trial in Denver, Orlando (Granulocyte Macrophage Colony Stimulation Factor)

      Active, not recruiting
      • Ependymoma, Recurrent Childhood
      • Ependymoma
      • Granulocyte Macrophage Colony Stimulation Factor
      • Denver, Colorado
      • +1 more
      Feb 8, 2022

      Locally Advanced Breast Cancer, Chemo Effect Trial in Beijing (inetetamab with pertuzumab and paclitaxel/carboplatin (TCbIP)

      Recruiting
      • Locally Advanced Breast Cancer
      • Chemotherapy Effect
      • inetetamab with pertuzumab and paclitaxel/carboplatin (TCbIP) regimen
      • Beijing, China
        National Cancer Center/National Clinical Research Center for Can
      Feb 28, 2023

      HIV Trial in Kericho (Env-C Plasmid DNA, HIV Env gp145 C.6980 protein, Rehydragel®)

      Active, not recruiting
      • HIV Infections
      • Env-C Plasmid DNA
      • +6 more
      • Kericho, Kenya
        Kenya Medical Research Institute/Walter Reed Project, Clinical R
      Feb 25, 2022

      Advanced or Metastatic Solid Tumors Trial in Tianjin (JS012, JS012 combine with chemo)

      Recruiting
      • Advanced or Metastatic Solid Tumors
      • JS012
      • JS012 combine with chemotherapy
      • Tianjin, Tianjin, China
        Tianjin Medical University Cancer Institute & Hospital
      May 19, 2022

      RR DLBCL; PD-1; CD20 Trial (F520+F007)

      Not yet recruiting
      • RR DLBCL; PD-1; CD20
      • (no location specified)
      Dec 17, 2021

      Multiple Myeloma Trial in Worldwide (Talquetamab, Teclistamab, Daratumumab)

      Recruiting
      • Multiple Myeloma
      • Edmonton, Alberta, Canada
      • +12 more
      Jan 27, 2023

      COVID-19, Vaccine Adverse Reaction, Sars-CoV-2 Infection Trial in Conakry (BBIBP-CorV, Sputnik V)

      Recruiting
      • COVID-19
      • +3 more
      • BBIBP-CorV
      • Sputnik V
      • Conakry, Guinea
      • +1 more
      Jun 7, 2022

      Solid Tumors Trial (SPX-101)

      Not yet recruiting
      • Solid Tumors
      • SPX-101
      • (no location specified)
      Feb 8, 2022

      Follicular Lymphoma, Marginal Zone Lymphoma, Mantle Cell Lymphoma Trial run by the NCI (Obinutuzumab, Venetoclax, Magrolimab)

      Recruiting
      • Follicular Lymphoma
      • +4 more
      • Bethesda, Maryland
        National Institutes of Health Clinical Center
      Jan 20, 2023

      COVID-19, Vaccine Reaction, SARS CoV 2 Infection Trial in Bamako (Ad26.COV2.S, NVX-CoV2373)

      Not yet recruiting
      • COVID-19
      • +3 more
      • Ad26.COV2.S
      • NVX-CoV2373
      • Bamako, Mali
        CVD-MALI
      Jun 7, 2022

      Neuroblastoma Trial in Worldwide (Data-collection)

      Recruiting
      • Neuroblastoma
      • Data-collection
      • Wien,, Vienna, Austria
      • +13 more
      Oct 28, 2022

      Healthy Adults Trial in Créteil (Solo 0.3 group, Solo 1 group, Solo 3 group)

      Recruiting
      • Healthy Adults
      • Solo 0.3 group
      • +5 more
      • Créteil, France
      • +2 more
      Sep 9, 2022

      Breast Cancer, Breast Tumors, Breast Cancer Female Trial in Germany (Ontruzant, Chemotherapy, Pertuzumab)

      Recruiting
      • Breast Cancer
      • +3 more
      • Heidelberg, Baden-Wuerttemberg, Germany
      • +10 more
      Aug 30, 2021

      Cutaneous Squamous Cell Carcinoma Trial in Waratah, Melbourne, Nedlands (Imgatuzumab)

      Suspended
      • Cutaneous Squamous Cell Carcinoma
      • Waratah, New South Wales, Australia
      • +2 more
      May 17, 2022

      Clear-Cell Renal Carcinoma Trial run by the NCI (rhIL-15, Avelumab)

      Terminated
      Has Results
      • Clear-Cell Renal Carcinoma
      • Bethesda, Maryland
        National Institutes of Health Clinical Center
      Apr 27, 2022

      HIV-1 Trial in Bethesda, New York (3BNC117-LS, 10-1074-LS, Sterile Saline)

      Recruiting
      • HIV-1
      • 3BNC117-LS
      • +2 more
      • Bethesda, Maryland
      • +1 more
      Jan 31, 2023